STAT+: Alzheimer’s conference preview: Aduhelm debate persists, while field grapples with new targets and directions

When physicians and scientists involved in Alzheimer’s disease gather in Boston next week for an annual conference known as CTAD — shorthand for Clinical Trials on Alzheimer’s Disease — they will wrestle with a research field in a holding pattern.

Aduhelm is available — the first treatment approved in two decades — but until there’s more information on its actual benefits and cost-effectiveness for patients, many physicians are sitting on the sidelines and waiting for additional data.

Continue to STAT+ to read the full story…